SEC Form 4 · accession 0001193125-26-297605
Cullinan Therapeutics, Inc. · CGEM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Michaelson
Officer — Chief Scientific Officer
Period of report
Jul 6, 2026
Accepted (ET)
Jul 7, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001789972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 6, 2026 | M | 4,000 | $4.30 | A | 170,844 | D | |
| Common StockF2 | Jul 6, 2026 | S | 8,000 | $17.82 | D | 162,844 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $4.30 | Jul 6, 2026 | M | 4,000 | D | — | Oct 28, 2030 | Common Stock | 4,000 | 112,987 | D |
Explanation of responses
- F1Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on August 7, 2025.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.35 to $18.19. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F325% of the shares vested on July 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter.